NEW YORK (GenomeWeb) – Rosetta Genomics today reported a 115 percent jump in its second quarter revenues, due to increased sales of the company's RosettaGX Reveal assay for the classification of indeterminate thyroid nodules (ITN).

The company also disclosed that the previously announced $2.9 million sale of its PersonalizeDx business has been delayed after the buyer, Pragmin Prognosis, failed to complete the transaction.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.